Literature DB >> 18557716

Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study.

Tae Y Lee1, Sang S Lee, Seok W Jung, Seong H Jeon, Sung-Cheol Yun, Hyoung-Chul Oh, Seunghyun Kwon, Sung K Lee, Dong W Seo, Myung-Hwan Kim, Dong J Suh.   

Abstract

OBJECTIVES: There is a wide variation in risk factors for intrahepatic cholangiocarcinoma (ICC) among various populations. Several studies have suggested that hepatitis C virus (HCV) infection may play a role in the development of ICC, whereas the role of hepatitis B virus (HBV) infection is less clear.
METHODS: To determine whether HBV or HCV infection is a risk factor of ICC, we compared baseline demographic and clinical factors in 622 patients diagnosed between 2000 and 2004 with histologically confirmed ICC and 2,488 healthy controls, matched 4:1 with ICC patients for sex and year of birth.
RESULTS: HBV infection (odds ratio [OR] 2.3, 95% confidence interval [CI] 1.6-3.3), but not HCV infection, was significantly related to ICC. Other significant risk factors for ICC included liver cirrhosis (OR 13.6), heavy alcohol consumption (OR 6.6), diabetes (OR 3.2), Clonorchis sinensis infection (OR 13.6), hepatolithiasis (OR 50.0), and choledochal cysts (OR 10.7).
CONCLUSIONS: Our results indicate that development of ICC seems to be more closely related to HBV infection than to HCV infection in Korea, where both HBV and ICC are endemic.

Entities:  

Mesh:

Year:  2008        PMID: 18557716     DOI: 10.1111/j.1572-0241.2008.01796.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  82 in total

Review 1.  Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma.

Authors:  William C Palmer; Tushar Patel
Journal:  J Hepatol       Date:  2012-03-13       Impact factor: 25.083

2.  99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: symbionts and immunopathology in chronic diseases: insights from evolution.

Authors:  P W Ewald
Journal:  Clin Exp Immunol       Date:  2010-04       Impact factor: 4.330

3.  Intrahepatic Cholangiocarcinoma With Lymphoepithelioma-like Carcinoma Components Not Associated With Epstein-Barr Virus: Report of a Case.

Authors:  Suefumi Aosasa; Tadashi Maejima; Akifumi Kimura; Kiyoshi Nishiyama; Hiromi Edo; Hiroshi Shinmoto; Tatsumi Kaji; Sho Ogata; Kazuo Hatsuse; Kazuo Hase; Junji Yamamoto
Journal:  Int Surg       Date:  2015-04

4.  Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.

Authors:  Wei-Feng Shen; Wei Zhong; Feng Xu; Tong Kan; Li Geng; Feng Xie; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

5.  Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study.

Authors:  W F Shen; W Zhong; Q Liu; C J Sui; Y Q Huang; J M Yang
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

Review 6.  Cholangiocarcinoma--controversies and challenges.

Authors:  Tushar Patel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 46.802

Review 7.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

Review 8.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

9.  Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea.

Authors:  Hai-Rim Shin; Jin-Kyoung Oh; Min Kyung Lim; Aesun Shin; Hyun-Joo Kong; Kyu-Won Jung; Young-Joo Won; Sohee Park; Sang-Jae Park; Sung-Tae Hong
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

10.  Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues.

Authors:  Ben-Dong Chen; Wen-Chao Zhao; Jian-Da Dong; Hui Sima
Journal:  Mol Biol Rep       Date:  2014-02-28       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.